Optimization of Busulfan Dosing Regimen in Pediatric Patients Using a Population Pharmacokinetic Model Incorporating GST Mutations.

Jinjie YuanNing SunXinying FengHuan HeDong MeiGuanghua ZhuLi-Bo Zhao

Published in: Pharmacogenomics and personalized medicine (2021)

We recommend a GSTA1-BSA and BSA-based dosing (Q6 h) based on a PPK model for personalizing busulfan therapy in pediatric population. Additionally, an optimal LSS (C2h and C4h) provides convenience for therapeutic drug monitoring (TDM) in the future.

Keyphrases

allogeneic hematopoietic stem cell transplantation
stem cells
current status
bone marrow
acute myeloid leukemia
mesenchymal stem cells
cell therapy
replacement therapy